Aristippos  Gennadios net worth and biography

Aristippos Gennadios Biography and Net Worth

Insider of Catalent
Aris Gennadios has served as our President, Softgel & Oral Technologies since September 2013. Previously, Dr. Gennadios served as Vice President and General Manager of Softgel Technologies. Dr. Gennadios has worked in the pharmaceutical industry since 1996 in roles including R&D, field sales, business development, operations, and leadership.

He joined Catalent’s predecessor company, Cardinal Health, in 2002 and has held several key leadership posts within the softgel technologies business including Global Vice President of Business Development for Softgel Technologies, General Manager of the Oral Development Center in Somerset, NJ, and Vice President and General Manager for Rx Softgel and Consumer Health products.

Dr. Gennadios earned his bachelor’s degree in chemical engineering from the National Technical University of Athens, Greece and his master’s degree in agricultural engineering from Clemson University. Dr. Gennadios holds a doctorate in engineering from the University of Nebraska and an MBA from Wake Forest University.

What is Aristippos Gennadios' net worth?

The estimated net worth of Aristippos Gennadios is at least $5.45 million as of August 24th, 2023. Dr. Gennadios owns 96,552 shares of Catalent stock worth more than $5,449,395 as of March 29th. This net worth evaluation does not reflect any other investments that Dr. Gennadios may own. Additionally, Dr. Gennadios receives an annual salary of $799,260.00 as Insider at Catalent. Learn More about Aristippos Gennadios' net worth.

How old is Aristippos Gennadios?

Dr. Gennadios is currently 58 years old. There are 8 older executives and no younger executives at Catalent. The oldest executive at Catalent is Mr. John J. Greisch M.B.A., Executive Chairman of the Board, who is 69 years old. Learn More on Aristippos Gennadios' age.

What is Aristippos Gennadios' salary?

As the Insider of Catalent, Inc., Dr. Gennadios earns $799,260.00 per year. The highest earning executive at Catalent is Mr. Alessandro Maselli, President, CEO & Director, who commands a salary of $1,080,000.00 per year. Learn More on Aristippos Gennadios' salary.

How do I contact Aristippos Gennadios?

The corporate mailing address for Dr. Gennadios and other Catalent executives is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. Catalent can also be reached via phone at (732) 537-6200 and via email at [email protected]. Learn More on Aristippos Gennadios' contact information.

Has Aristippos Gennadios been buying or selling shares of Catalent?

Aristippos Gennadios has not been actively trading shares of Catalent during the last ninety days. Most recently, Aristippos Gennadios sold 396 shares of the business's stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $44.49, for a transaction totalling $17,618.04. Following the completion of the sale, the insider now directly owns 96,552 shares of the company's stock, valued at $4,295,598.48. Learn More on Aristippos Gennadios' trading history.

Who are Catalent's active insiders?

Catalent's insider roster includes Jonathan Arnold (Insider), Thomas Castellano (CFO), John Chiminski (CEO), Steven Fasman (SVP), Karen Flynn (Insider), Mario Gargiulo (SVP), Aristippos Gennadios (Insider), John Greisch (Insider), Michael Grippo (SVP), Scott Gunther (SVP), Thomas Hawkeswood (Insider), Ricky Hopson (CAO), Wetteny Joseph (CFO), Charles Lickfold (SVP), Gregory Lucier (Director), Alessandro Maselli (COO), Ricardo Pravda (SVP), Michael Riley (Insider), Michelle Ryan (Director), Kay Schmidt (SVP), Ricci Whitlow (Insider), and Peter Zippelius (Director). Learn More on Catalent's active insiders.

Are insiders buying or selling shares of Catalent?

In the last year, Catalent insiders bought shares 2 times. They purchased a total of 22,000 shares worth more than $1,105,020.00. In the last year, insiders at the sold shares 10 times. They sold a total of 7,953 shares worth more than $375,228.99. The most recent insider tranaction occured on March, 15th when SVP Scott Gunther sold 387 shares worth more than $21,749.40. Insiders at Catalent own 0.3% of the company. Learn More about insider trades at Catalent.

Information on this page was last updated on 3/15/2024.

Aristippos Gennadios Insider Trading History at Catalent

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2023Sell396$44.49$17,618.0496,552View SEC Filing Icon  
8/27/2021Sell2,262$131.13$296,616.06View SEC Filing Icon  
7/26/2021Sell465$113.05$52,568.25View SEC Filing Icon  
12/21/2020Sell13,662$102.84$1,405,000.08View SEC Filing Icon  
6/25/2020Sell8,325$73.00$607,725.00View SEC Filing Icon  
11/25/2019Sell45,256$52.55$2,378,202.80View SEC Filing Icon  
3/21/2019Sell3,392$42.18$143,074.56View SEC Filing Icon  
See Full Table

Aristippos Gennadios Buying and Selling Activity at Catalent

This chart shows Aristippos Gennadios's buying and selling at Catalent by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Catalent Company Overview

Catalent logo
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.
Read More

Today's Range

Now: $56.44
Low: $56.38
High: $56.75

50 Day Range

MA: $55.84
Low: $49.19
High: $59.82

2 Week Range

Now: $56.44
Low: $31.45
High: $68.08

Volume

1,839,464 shs

Average Volume

2,827,563 shs

Market Capitalization

$10.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2